Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread

被引:46
|
作者
Mahlakoiv, Tanel [1 ,2 ]
Ritz, Daniel [3 ]
Mordstein, Markus [1 ,2 ]
DeDiego, Marta L. [4 ]
Enjuanes, Luis [4 ]
Mueller, Marcel A. [3 ]
Drosten, Christian [3 ]
Staeheli, Peter [1 ]
机构
[1] Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany
[2] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany
[3] Univ Bonn, Inst Virol, Med Ctr, D-53127 Bonn, Germany
[4] CSIC, CNB, Dept Mol & Cell Biol, E-28049 Madrid, Spain
来源
关键词
IFN-LAMBDA; SYNDROME SARS; INFECTION; RECEPTOR; INVOLVEMENT; PATHWAY;
D O I
10.1099/vir.0.046284-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
STAT1-deficient mice are more susceptible to infection with severe acute respiratory syndrome coronavirus (SARS-CoV) than type I interferon (IFN) receptor-deficient mice. We used mice lacking functional receptors for both type I and type III IFN (double knockout, dKO) to evaluate the possibility that type III IFN plays a decisive role in SARS-CoV protection. We found that viral peak titres in lungs of dKO and STAT1-deficient mice were similar, but significantly higher than in wild-type mice. The kinetics of viral clearance from the lung were also comparable in dKO and STAT1-deficient mice. Surprisingly, however, infected dKO mice remained healthy, whereas infected STAT1-deficient mice developed liver pathology and eventually succumbed to neurological disease. Our data suggest that the failure of STAT1-deficient mice to control initial SARS-CoV replication efficiently in the lung is due to impaired type I and type III IFN signalling, whereas the failure to control subsequent systemic viral spread is due to unrelated defects in STAT1-deficient mice.
引用
收藏
页码:2601 / 2605
页数:5
相关论文
共 32 条
  • [31] Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study
    Spinelli, Matthew A.
    Peluso, Michael J.
    Lynch, Kara L.
    Yun, Cassandra
    Glidden, David, V
    Henrich, Timothy J.
    Deeks, Steven G.
    Gandhi, Monica
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E916 - E919
  • [32] Differentiating patients admitted primarily due to coronavirus disease 2019 (COVID-19) from those admitted with incidentally detected severe acute respiratory syndrome corona-virus type 2 (SARS-CoV-2) at hospital admission: A cohort analysis of German hospital records
    Strobl, Ralf
    Misailovski, Martin
    Blaschke, Sabine
    Berens, Milena
    Beste, Andreas
    Krone, Manuel
    Eisenmann, Michael
    Ebert, Sina
    Hoehn, Anna
    Mees, Juliane
    Kaase, Martin
    Chackalackal, Dhia J.
    Koller, Daniela
    Chrampanis, Julia
    Kosub, Jana-Michelle
    Srivastava, Nikita
    Albashiti, Fady
    Gross, Uwe
    Fischer, Andreas
    Grill, Eva
    Scheithauer, Simone
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (06) : 746 - 753